Watts Gwilliam & Co’s Novo Nordisk NVO Stock Holding History

Watts Gwilliam & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,994	Closed	-$1.52M	–	220
2024 Q3	$1.52M	Buy	+12,994	New	+$1.73M	0.33%	62

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Watts Gwilliam & Co's NVO Position: Q4 2024 in Review

Watts Gwilliam & Co sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 12,994 shares — an estimated $1.52M sold.

Watts Gwilliam & Co first reported a position in NVO in Q3 2024 and held it in 1 quarter. The position peaked at $1.52M in Q3 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

Watts Gwilliam & Co reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
Watts Gwilliam & Co sold 12,994 Novo Nordisk shares in Q4 2024, an estimated $1.52M.
Watts Gwilliam & Co first reported a position in Novo Nordisk in Q3 2024 and held it in 1 quarter.
Watts Gwilliam & Co's Novo Nordisk position peaked at $1.52M in Q3 2024.
1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Watts Gwilliam & Co's 13F filing for Q4 2024, filed 10 Jan 2025.